<DOC>
	<DOCNO>NCT02040220</DOCNO>
	<brief_summary>This prospective , non-interventional , multi center post-authorization safety study include patient diagnosis CRVO . The investigator make choice treatment ( EYLEA ) well decision use EYLEA accord Japanese Package Insert prior enrol patient study . The observation period patient start therapy EYLEA initiate . The enrollment period 2 year . Patients follow time period 2 year longer possible ( e.g . lose follow-up ) within 2 year . For patient , data collect defined case report form initial visit , follow-up visit final visit , either routine clinical visit ( per investigator routine practice ) . There interim analysis study data : 6 month last patient first visit J-PSUR ( Japanese-Periodic Safety Update Report )</brief_summary>
	<brief_title>Prospective , Non-interventional , Multi-center Post-authorization Safety Study Eylea Central Retinal Vein Occlusion ( CRVO )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Patients start EYLEA treatment CRVO Patients already receive EYLEA treatment Patients contraindicate base approve label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CRVO , Macular edema , Aflibercept , anti-VEGF</keyword>
</DOC>